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nternalization of activated receptors regulates signaling,
and endocytic adaptor proteins are well-characterized
in clathrin-mediated uptake. One of these adaptor pro-
teins, huntingtin interacting protein 1 (HIP1), induces cellu-
lar transformation and is overexpressed in some prostate
cancers. We have discovered that HIP1 associates with the
androgen receptor through a central coiled coil domain
and is recruited to DNA response elements upon androgen
stimulation. HIP1 is a novel androgen receptor regulator,
I
 
signiﬁcantly repressing transcription when knocked down
using a silencing RNA approach and activating tran-
scription when overexpressed. We have also identiﬁed a
functional nuclear localization signal at the COOH termi-
nus of HIP1, which contributes to the nuclear transloca-
tion of the protein. In conclusion, we have discovered that
HIP1 is a nucleocytoplasmic protein capable of associat-
ing with membranes and DNA response elements and
regulating transcription.
 
Introduction
 
Endocytosis is important for receptor internalization, nutrient
uptake, antigen presentation, pathogen internalization, and
maintenance of plasma membrane surface area. Endocytosis
occurs via several distinct pathways and requires coordinated
interactions between a variety of molecules at the membrane and
cell cortex. In yeast, a functional connection between the actin
cytoskeleton and endocytosis has been firmly established (Geli
and Riezman, 1998). Mutations in actin and in several actin-
binding proteins inhibit both receptor-mediated and fluid-phase
endocytosis (Kubler and Riezman, 1993; Munn et al., 1995).
To gain insights into the roles of actin in endocytosis, it
was important to identify actin-binding proteins with a func-
tional involvement in endocytosis. Sla2p was one of the first to
be identified in a synthetic lethal screen in yeast against a null
allele of 
 
ABP1
 
, a gene encoding an actin-binding protein impli-
cated in cytoskeletal regulation, endocytosis, and cAMP sig-
naling. Sla2p is a peripheral membrane protein that contains a
novel NH
 
2
 
-terminal domain, three putative coiled coil domains,
a putative leucine zipper, and a COOH-terminal talin-like domain
(Holtzman et al., 1993; Wesp et al., 1997). Sla2p binds to F-actin
in vitro through the talin-like domain and partially colocalizes
with F-actin in cortical patches (McCann and Craig, 1997; Yang
et al., 1999).
Homologues of Sla2p have since been identified in nem-
atodes (
 
ZK370
 
.
 
3
 
) and humans (HIP1 and HIP1R). Huntingtin
interacting protein 1 (HIP1) is predominantly expressed in
brain and was first identified in a yeast two-hybrid screen for
interacting partners of huntingtin (Kalchman et al., 1997;
Wanker et al., 1997). Huntington’s disease is an inherited neu-
rodegenerative disorder caused by expansion of the codon
CAG in the huntingtin gene, which leads to expression of a
polyglutamine tract in the protein (Reddy et al., 1999). The af-
finity of the huntingtin protein–HIP1 interaction is inversely
correlated to the polyglutamine repeat length (Kalchman et al.,
1997). HIP1 is a 116-kD AP180 NH
 
2
 
-terminal homology
(ANTH) domain–containing protein capable of binding to
phosphatidylinositol lipids and recruiting clathrin via a short
peptide motif of the LLMDMD type in the vicinity of a central
coiled coil domain (Mishra et al., 2001; Hyun et al., 2004).
Consequently, much of the functional work on the HIP1 fam-
ily has focused on its ability to modulate actin dynamics in
clathrin-mediated endocytosis.
However, HIP1 was recently found to be overexpressed
in a subset of cancers of the prostate and colorectum (Rao et al.,
2002). Prostate cancer is a disease, which in its advanced form
is associated with changes in the transcriptional response and
expression of a polyglutamine repeat–containing transcription
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factor, the androgen receptor (AR; Chen et al., 2004). The AR
is a member of the nuclear hormone receptor superfamily of
transcription factors. The AR consists of an NH
 
2
 
-terminal do-
main containing polyglutamine and polyglycine repeats, which
interacts with a series of transcriptional coregulators; a zinc
finger DNA-binding domain; a hinge region encompassing nu-
clear localization signals; an acetylation site; and a COOH-ter-
minal ligand-binding domain. The nuclear translocation of this
transcription factor is dependent on the binding of androgen by
the COOH-terminal ligand-binding domain. An actin-binding
protein, filamin, was recently shown to interact with the recep-
tor and to be required for translocation (Ozanne et al., 2000).
A subset of endocytic adaptor proteins including Eps15
and Epsin1 have been reported to undergo nucleocytoplasmic
shuttling on the basis that their steady-state distribution be-
comes nuclear upon treating cells with an antifungal antibiotic,
Leptomycin B, which inhibits nuclear export (Hyman et al.,
2000; Vecchi et al., 2001). A strong argument against a nuclear
distribution of these proteins is the absence of a nuclear sub-
fraction under untreated conditions, although this can be ex-
plained by a high rate of nuclear export. A potential nuclear
function for Eps15 and CALM was reported to be the regula-
tion of transcription on the basis of their modulatory effects us-
ing a GAL4-based transactivation assay (Vecchi et al., 2001).
In this study, we have examined the effects of androgen
treatment on the subcellular distribution of HIP1 and the ef-
fects of this protein on AR-mediated transcription. We have
uncovered a functional association of HIP1 with androgen re-
sponse elements (AREs), providing the first direct evidence for
transcriptional modulation of hormone-responsive genes by an
endocytic adaptor.
 
Results
 
HIP1 is both nuclear and cytosolic
 
A characteristic of prostatic tissue is a transcriptional response
to androgen, which is mediated by the AR. We used an AR
expressing prostate cancer cell line LNCaP to examine by
subcellular fractionation changes in the distribution of the en-
dogenous AR and HIP1 in response to treatment with a synthetic
androgen, Mibolerone. Treating LNCaP cells with Mibolerone
resulted in a 70% increase in nuclear AR but also resulted in a
nuclear redistribution of HIP1 of up to 50% (Fig. 1 C). In con-
trast, clathrin, a binding partner of HIP1, remained entirely
cytosolic (Fig. 1 A). This nuclear translocation was observed
using confocal microscopy after Mibolerone treatment (Fig. 1 B).
Translocation of endogenous AR and HIP1 was also induced
by treating LNCaP cells with the physiological androgen dihy-
drotestosterone (unpublished data).
 
HIP1 associates with the AR
 
HIP1 was first identified as an interacting partner of a poly-
glutamine repeat–containing protein, huntingtin, in a yeast two-
hybrid screen with a binding affinity inversely proportional to
the size of the polyglutamine tract (Wanker et al., 1997). We
tested whether HIP1 also interacts with the AR, also a poly-
glutamine repeat–containing protein, using immunoprecipitation.
Endogenous AR and HIP1 were coimmunoprecipitated from
the LNCaP cell line (Fig. 2 A). This has been confirmed inde-
pendently by band identification using mass spectroscopy (un-
published data). We have also confirmed this interaction using
transfected COS7 cells in a mammalian two-hybrid screen with
the AR coactivator Tip60 as a positive control (Brady et al.,
1999; unpublished data).
We used a GAL4-based transactivation assay in an at-
tempt to identify domains of HIP1 with potential nuclear
functions (Fig. 2 B). Expression constructs encoding the
GAL4 DNA-binding domain fused to full-length HIP1, a con-
struct bearing the FxDxF/coiled coil and I/LWEQ domains
(
 
 
 
ANTH), and a construct consisting of the COOH-terminal
I/LWEQ domain alone were cotransfected along with a reporter
plasmid encoding the luciferase gene under the transcriptional
control of a GAL4-responsive promoter into AR-null COS7
cells. GAL4-HIP1 and GAL4-
 
 
 
ANTH produced a three- to
fourfold transactivation over the basal value produced by
GAL4 alone (Fig. 2 B). Although the degree of transactivation
was lower than that produced by E2F1, an established trans-
Figure 1. HIP1 is found in a nuclear subcellular fraction. (A) LNCaP cells
were fractionated after Mibolerone or vehicle treatment. Nuclear (N) and
cytosolic (C) fractions were resolved by SDS-PAGE (50  g per lane), trans-
ferred to nitrocellulose, and blotted for the AR, HIP1, lamin B, and clathrin,
illustrated here with representative blots. (B) LNCaP cells were grown in
steroid-depleted media for 48 h and then treated with 10 nM Mibolerone
or ethanol. HIP1 was detected using mouse mAb and the AR was detected
using a rabbit polyclonal antibody. The nuclei were stained with DAPI.
Bar, 70  m. (C) The degree of translocation of the AR and HIP1 was
quantitated by densitometric analysis of the blots. Data shown represent
the means of five independent experiments   SD. 
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activator, it was statistically significant and at a similar level
to that observed for endocytic proteins previously reported to
undergo nucleocytoplasmic shuttling (Vecchi et al., 2001).
We attempted to narrow down the binding site for the AR
in HIP1 by expressing and purifying GST-tagged domain con-
structs of HIP1 encompassing the coiled coil domain, the
coiled coil/DxF region, and the COOH-terminal I/LWEQ do-
main from 
 
Escherichia coli
 
. We then incubated these recombi-
nant domains with lysate extracted from COS7 cells trans-
fected with the AR and, after immunoprecipitation with a
polyclonal AR antibody, blotted for the AR, GST, and HIP1.
Equal quantities of the AR were immunoprecipitated in the
conditions used. A HIP1 blot detected an association with the
FxDxF/coiled coil domain and this was confirmed using an
antibody raised against GST (Fig. 2 C). From these data we
conclude that HIP1 and the AR associate, and that this associa-
tion requires the central FxDxF/coiled coil domain of HIP1.
 
HIP1 is a transcriptional regulator of 
hormone receptors
 
We investigated the effects of ectopic HIP1 expression on the
transcriptional activity of the AR using a luciferase reporter
construct driven by a prostate-specific antigen (PSA) promoter,
pPSALuc. COS7 cells were cotransfected with the AR and in-
creasing quantities of HIP1. The transcriptional response to an-
drogen stimulation was enhanced in a dose-dependent manner
with a maximal fourfold enhancement above the stimulatory
level achieved in the absence of HIP1 (Fig. 3 A). Coactivation
was selectively blocked with an anti-androgen, bicalutamide (Ca-
sodex; Fig. 3 A). HIP1-dependent coactivation is therefore un-
likely to be a cross talk effect occurring through AR-independent
Figure 2. Association between HIP1 and the AR. (A) LNCaP cells were
transiently transfected with 2  g pcDNA3-AR and pcDNA3-Myc-HIP1 per
90-mm dish. Cell lysates were immunoprecipitated with an anti-AR anti-
body and immunoblotted with an anti-AR polyclonal antibody and an
anti-HIP1 mAb. (B) HIP1 acts as a transcriptional regulator in GAL4-based
assays. COS-7 cells were cotransfected with a GAL4-regulated luciferase
reporter construct, and chimeric constructs encompassing the GAL4 DNA-
binding domain fused to HIP1 and the following domains: ANTH (encom-
passing aa 1–310),  ANTH (encompassing aa 320–1037), and I/LWEQ
(encompassing aa 800–1037). Luciferase activity was measured 48 h af-
ter transfection on equal amounts of total cellular lysates that expressed
comparable levels of the various GAL4 fusion proteins as assessed by anti-
GAL4 immunoblot (inset). Graphed data represent the means of three in-
dependent experiments with error bars for the SD. (C) COS7 cells were
transfected with 2  g pcDNA3-AR per 9-cm dish. Lysates were prepared
and the AR was immunoprecipitated from 300  g of lysate supplemented
with 10  g of recombinant proteins. The left panel is a Coomassie-stained
gel illustrating the equivalent loading of GST (lane 1), GST-ANTH domain
(lane 2), GST-FxDxF/coiled coil domain encompassing aa 320–800 (lane
3), and GST-I/LWEQ domain (lane 4). Immunoprecipitates were blotted
for AR, HIP1, and GST as indicated.
Figure 3. HIP1 is a transcriptional coregulator for the AR. (A) COS7 cells
were transfected with 50 ng pcDNA3-AR plus increasing quantities of
pcDNA3-HIP1 (0, 50, 100, 200, and 400 ng) together with 100 ng of a
pPSA luciferase reporter construct (pPSALuc). Cells were treated with10 nM
Mibolerone   1  M bicalutamide (Casodex) for 48 h and luciferase activ-
ity was normalized for transfection efficiency as determined by  -galac-
tosidase assays and expressed relative to vehicle-treated singly transfected
AR-positive cells. Data shown represent the means of three independent
experiments   SD. (insets) Lysates were prepared and run at 50  g per
lane before blotting for HIP1 and AR. (B) COS7 cells were transfected with
50 ng pcDNA3-AR plus increasing quantities of pcDNA3-HIP1 (0, 50,
100, 200, and 400 ng) together with 100 ng of a minimal ARE luciferase
reporter construct (pARE4-Luc). After 48 h, cells were lysed and luciferase
assays were performed as described. Data shown represent the means of
three independent experiments   SD. 
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signaling. Coactivation was also observed when a minimal ARE
reporter construct was used, further arguing against surrogate
effects on the activities of other transcription factors (Fig. 3 B).
To determine whether the effects on AR-mediated tran-
scription reflected an association between HIP1 and AREs, or
were less direct, chromatin immunoprecipitations (ChIP) were
undertaken using antibodies against HIP1 and the AR. Se-
quences corresponding to the proximal (AREI) and distal
(AREIII) AREs were amplified by PCR (Fig. 4 A). ChIP as-
says were performed over 4 h after treatment of LNCaP cells
with Mibolerone. A temporal recruitment of HIP1 and the AR
to both AREI and AREIII was observed, though the temporal
recruitment of HIP1 differed somewhat from that of the AR
(Fig. 4 B). HIP1 was recruited within 1 h of Mibolerone treat-
ment to AREI at levels that were sustained over the 4-h treat-
ment period in contrast to the biphasic recruitment of the AR,
which peaked at 1 and 4 h maxima. Recruitment of the AR to
AREIII was also biphasic, resembling the pattern of recruit-
ment to AREI (Fig. 4 B). In contrast, the recruitment of HIP1 to
AREIII was monophasic with maximal recruitment detectable
1 h after stimulation with Mibolerone. In a reChIP assay, im-
munoprecipitated chromatin extracts were blotted for HIP1 and
the AR after 2 h of treatment with Mibolerone. HIP1 and the
AR were reciprocally immunoprecipitated and associated with
AREI but not with a non-ARE–containing region of the PSA
promoter (AREX; Fig. 4 C).
Synchronous AR binding is not a requisite for the associa-
tion of HIP1 with AREs, and HIP1 may therefore potentially as-
sociate with other promoters/response elements and regulate the
transcriptional activity of other nuclear hormone nuclear recep-
tors. Indeed, cotransfection of HIP1 with 
 
 
 
 and 
 
 
 
 isoforms of
the estrogen receptor enhanced their transcriptional response to
estradiol treatment. The coactivation effect of HIP1 was appre-
ciably greater than that of one of the best-characterized estrogen
receptor coactivators, p300 (Fig. S1, A and B, available at http://
www.jcb.org/cgi/content/full/jcb.200503106/DC1; Hanstein et
al., 1996). Furthermore, increasing quantities of HIP1 cotrans-
fected into COS-7 cells along with the glucocorticoid receptor
produced progressive transcriptional coactivation of this recep-
tor (Fig. S1 C). Interestingly, when HIP1 is cotransfected into
COS7 cells along with a fusion of GAL4 with the ligand-bind-
ing domain (GAL4-LBD) of the glucocorticoid receptor, no ad-
ditional transcriptional enhancement is observed (Fig. S1 D).
This implies that the effects of HIP1 on other nuclear hormone
receptors may depend on the NH
 
2
 
-terminal domains of these
proteins. HIP1 therefore affects the transcriptional activity of
other members of the nuclear hormone receptor family and this
is characteristic of many AR coregulators.
 
HIP1 levels affect the rate of AR 
degradation
 
We examined whether endogenous HIP1 was also required to
sustain AR transcriptional activity by taking a silencing RNA
(siRNA) approach to knockdown HIP1 in LNCaP cells (Fig.
5 A). HIP1 levels were reduced by 70–80% using this ap-
proach, as were levels of PSA, an androgen-responsive gene
product for which AR activity is required. Protein levels of the
AR were also reduced and quantitative reverse transcriptase
PCR for HIP1, HIP1R, AR, and PSA was used to determine
whether the reduction in the protein levels was reflected at the
mRNA level. HIP1 mRNA was significantly reduced as pre-
dicted from the siRNA targeting of this protein, as were the
mRNA levels of PSA, which reflects both the decreased level
of AR in the treated cells and perhaps reduced transcriptional
activity although it was not possible to differentiate between
these two factors (Fig. 5 B). Strikingly, the mRNA levels of the
AR itself were unaffected, and this implied that the reduction in
the protein levels of the AR reflected an effect on protein rather
than mRNA turnover. We explored this further by repeating the
siRNA experiment and at 36 h after treatment inhibiting new
protein synthesis by treating the cells with cycloheximide. Ly-
sates were then prepared at two hourly time points after the ap-
plication of the cycloheximide block and blotted for the AR,
HIP1, and 
 
 
 
-tubulin. The half-life of the AR was found to be
reduced threefold in cells treated with siRNA-targeting HIP1
versus control siRNA (Fig. 5 C). HIP1 therefore reduces the
rate of AR degradation. It is not currently known what the
mechanism for AR degradation may be. There is evidence that
the AR is ubiquitinated and that this enhances its transcrip-
tional activity, whereas treatment with proteasomal inhibitors
reduces the rate of AR dissociation from the AREs and AR-
mediated transcription (Beitel et al., 2002; Burgdorf et al.,
2004). However, treatment of cells with MG132, a proteasomal
inhibitor, has not been shown to increase the protein levels of
Figure 4. HIP1 associates with ARE. (A) Schematic diagram of the PSA
promoter and ChIP assay with the length of PCR products denoted by a
black bar. (B) ChIP was performed in LNCaP cells using both HIP1 and AR
antibodies over a 4-h androgen time course. PCR was performed for AREs
I and III. (C) ReChIP assays were performed in LNCaP cells by reprobing
AR immunocomplexes with AR and HIP1 antibodies after 2-h androgen
treatment. AR-HIP1 association was analyzed at ARE I and a non-ARE–
containing portion of the PSA promoter (AREX). 
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the AR appreciably and so a direct link between AR ubiquitina-
tion and AR degradation is yet to be made (Tanner et al., 2004).
 
Transcriptional regulation by HIP1 is 
distinct from lipid binding and requires a 
COOH-terminal NLS
 
HIP1 has in the past been reported to play a role as an adaptor in
clathrin-dependent membrane trafficking of growth factor recep-
tors through the binding of phosphoinositides and clathrin
(Hyun et al., 2004). It was therefore important to dissect the
transcriptional effects of HIP1 from its other established func-
tions. To do this, mutations were made in the phosphoinositide-
binding ANTH domain of HIP1 based on the strong homology
with other ANTH domain–containing proteins (Fig. 6 A). The
crystal structure of the ANTH domain of clathrin assembly lym-
phoid myeloid leukemia protein (CALM) in complex with a sol-
uble short-chain (diC
 
8
 
) L-
 
 
 
-D-
 
myo
 
-phosphatidylinositol-4,5-
bisphosphate has been resolved and the strong homology with
HIP1 therefore enabled us to identify conserved basic residues
predicted to lie in the lipid binding pocket (Ford et al., 2001).
Two conserved lysine residues were mutated (K56E/K58E) and
the effects of these HIP1 mutations were tested using bacterially
expressed wild-type and mutant HIP1 ANTH domains (HIP1N;
amino acids 1–310) in a liposome sedimentation assay. Mutation
of the equivalent conserved residues in 
 
Saccharomyces cerevisiae
 
Sla2p (Lysines-24 and -26 to alanine) result in the complete ab-
lation of lipid binding (Sun et al., 2005). In our study, neither the
wild-type nor the mutant construct bound efficiently to control
Figure 5. Silencing HIP1 expression reduces the transcriptional activity
and protein levels of the AR. (A) LNCaP cells were transfected with a com-
bination of HIP1 siRNAs versus a control siRNA. After 48 h, cell lysates
were blotted for HIP1, HIP1R, AR, PSA, and tubulin. (B) Relative expres-
sion of AR, actin, HIP1, HIP1R, and PSA genes in LNCaP cells analyzed
by real-time RT-PCR after transfection with either scrambled control or HIP1
siRNA. The data represent experimental triplicates normalized to actin lev-
els from cells treated with a scrambled control siRNA and the error bars
correspond to the SD on this data. (C) LNCaP cells were transfected with
HIP1 siRNA or a scrambled control siRNA. After 40 h, cells were treated
with cycloheximide (CHX). Cells were lysed during the course of the fol-
lowing 8 h with Western blot analysis of AR levels. Lysates were also
probed by Western blotting for tubulin as a loading control.
Figure 6. The effects of the K56E/K58E double mutation on lipid binding
by HIP1. (A) A sequence alignment of the putative  1-to- 2 loop region of
HIP1 with that of other ANTH domain proteins based on the crystal struc-
ture of the CALM (Altschul et al., 1997; Ford et al., 2001). Note key lipid
binding residues (red); sequence identity (red); mutated residues (red ar-
rowheads); and predicted NLS using http://cubic.bioc.columbia.edu/
cgi/var/nair/resonline.pl (blue amino acids). Sequence identifications:
HsHIP1 (NP_005329), HsHIP1R (NP_003950), Sp putative clathrin coat
assembly protein (NP_596345), ScSla2p (NP_014156), Xl Hip1-prov
protein (AAH77182), and RnAP180 (CAA48748). Hs, Homo sapiens;
Sc, Saccharomyces cerevisiae;  Sp, Schizosaccharomyces pombe; Xl,
Xenopus laevis; Rn, Rattus norvegicus. An I/LWEQ module sequence
alignment prepared using CLUSTALW incorporating the predicted fourth  
helix of the module is shown (McCann and Craig, 1999). Additional se-
quence identifiers: HsTalin1 (AAF27330) and SpSla2p (NP_594069). (B)
Coomassie-stained gel of a sedimentation assay with phosphatidylinositol
(PI) and brain (Folch) liposomes. P, pellet; S, supernatant. Liposomes
were incubated with 5  M of the indicated proteins: GST, GST-HIP1N
(aa 1–310), GST-HIP1N K/E (aa 1–310 K56E/K58E). (C) Isolation of an
enriched clathrin-coated vesicle fraction from LNCaP cells. LNCaP cells
were transfected with pcDNA3 HIP1 R1005E or HIP1 K56E/K58E or vec-
tor alone. 48 h posttransfection they were disrupted by homogenization
and CCV fractions were isolated using a protocol adapted from Hirst et
al. (2004). Coomassie blue–stained gel (left) and Western blots of equal
protein loadings of homogenate (H), high speed supernatant (HSS), and
CCV fractions from the isolation procedure. 
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liposomes but the wild-type HIP1 ANTH domain bound effec-
tively to liposomes produced from bovine brain lipid extract
(Folch lipids; Fig. 6 B). However, the double lysine mutation
knocked out lipid binding as predicted.
To determine whether the K56E/K58E mutation affected
the subcellular distribution of HIP1, LNCaP cells were trans-
fected with Myc-His HIP1 or the HIP1 K56/K58E double mu-
tant. Enriched clathrin-coated vesicle fractions were prepared
and blotted for clathrin, HIP1, and adaptors. The double mutant
of HIP1 was significantly de-enriched from the CCV fraction
relative to the wild-type protein (Fig. 6 C). The lipid binding
mutation may therefore increase the size of the “free” or cyto-
solic pool of HIP1 available to associate with the AR and/or al-
ternative scaffolds such as DNA response elements and tran-
scription complexes.
The COOH-terminal I/LWEQ domain has regularly
spaced, conserved amino acids believed to comprise four
 
 
 
-helices, and in Sla2p and HIP1R this domain binds to F-actin
(Engqvist-Goldstein et al., 1999; Legendre-Guillemin et al.,
2002). Mutation of a conserved residue, arginine-958, in Sla2p
ablates actin binding (McCann and Craig, 1999). Although by
sequence alignment this arginine residue (R1005) is also present
in HIP1, there is only limited biochemical evidence for an asso-
ciation between a recombinantly expressed I/LWEQ domain
fragment and actin (Senetar et al., 2004). Indeed binding is ab-
sent if a larger expression construct incorporating an upstream
 
 
 
-helix (USH) is used in the same binding assay. Other groups
have also been unable to detect actin binding with expression
constructs encompassing the entire talin-like (I/LWEQ) do-
main (Legendre-Guillemin et al., 2002).
Given this ambiguity and in light of the nuclear role that
we have uncovered for HIP1, we undertook algorithmic
searches for other motifs within this COOH-terminal do-
main. We identified a putative NLS at the COOH terminus be-
tween amino acids 996 and 1009 resembling the consensus
RK]x[RK]x[KR]x[4–6]RKK, which is strikingly absent in
other proteins with talin-like domains (Fig. 6 A; Cokol et al.,
2000). This implied an alternative role for R1005 in nuclear
transport. We therefore mutated this residue to a glutamate and
tagged GFP expression vectors with the HIP1 NLS, the mu-
tated NLS, and the equivalent sequence region in HIP1R. Con-
focal imaging revealed that the GFP-HIP1 construct has an in-
complete but clear nuclear colocalization in comparison to
GFP-HIP1R (Fig 7, A and B). Subcellular fractionation re-
vealed that this amounted to an approximate doubling in the
amount of nuclear GFP when compared with GFP-HIP1R, the
R1005E mutant, or GFP alone (Fig. 7, C and D). This indicates
that an NLS within HIP1 itself can contribute to nuclear import
and predicts an interaction between HIP1 and importins. A
large number of imported proteins contain multiple or bipartite
NLS motifs, which cumulatively result in high efficiency of
import. Given the fact that the AR contains NLS motifs in its
hinge region, we cannot rule out the possibility that other NLS-
containing proteins may translocate into the nucleus in a com-
plex with HIP1. This would explain why, in COS7 cells
cotransfected with HIP1 and the AR, the nuclear translocation
of both is androgen-reponsive and more efficient than that of
the GFP-tagged minimal NLS (Georget et al., 2002; Saporita et
al., 2003).
On the basis of this preliminary characterization of the
HIP1 mutants, we predicted that the lipid binding mutant (K56E/
K58E) might enhance the ability of HIP1 to coactivate the AR
by increasing the available cytosolic pool of HIP1 for nuclear
import. We also hypothesized that reducing nuclear import with
the R1005E mutation might conversely reduce the transcrip-
tional activity of the AR by having a dominant negative effect on
the nuclear import of both HIP1 and, owing to their association,
the AR. To test this, we transfected mutant and wild-type HIP1
into COS7 cells and examined the Mibolerone response of the
pPSALuc reporter construct. The K56E/K58E HIP1 mutant pro-
duced a twofold greater enhancement of transcription than wild-
type HIP1 under conditions of androgen stimulation (Fig. 8 A).
In contrast, the R1005E mutation repressed transcriptional activ-
Figure 7. Characterization of an NLS at the COOH terminus of HIP1.
COS7 cells were transfected with GFP-HIP1R (aa 992–1009; A) or GFP-
HIP1NLS (aa 992–1009; B) 48 h before imaging and fixation. Nuclei
were stained with DAPI. GFP-HIP1R is predominantly cytosolic, whereas
GFP-HIP1 has a nucleocytoplasmic distribution. Bars, 80  m. (C) COS7
cells were transfected with GFPHIP1, GFPHIP1_R1005E, GFPHIP1R, and
GFP alone and were fractionated to give nuclear (N) and cytoplasmic (C)
fractions, which were resolved by SDS-PAGE (50  g per lane) and blotted
for GFP, lamin B, and clathrin. (D) The degree of translocation of GFP,
GFPHIP1, GFPHIP1_R1005E, GFPHIP1R, and clathrin was quantitated by
densitometric analysis. Data shown represent the means of five independent
experiments   SD. 
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ity by fourfold. Examining androgen-treated cells expressing the
R1005E mutant we noted that there was a reduction in the appar-
ent nuclear translocation of the AR in cells coexpressing the AR
and the mutant (Fig. 8 B and Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200503106/DC1).
 
Discussion
 
Nuclear translocation of membrane 
trafficking proteins
 
It has previously been proposed that certain endocytic proteins
undergoing nucleocytoplasmic shuttling might function as pro-
tein scaffolds in the nucleus and exert regulatory effects on tran-
scription (Vecchi et al., 2001). Endocytic proteins first reported
to undergo nucleocytoplasmic shuttling were not found to be
stimulated to translocate to the nucleus upon treatment with epi-
dermal growth factor or phorbol ester (Vecchi et al., 2001). In
contrast, we report here that HIP1 translocates to the nucleus
and that this translocation is androgen inducible (Fig. 1). The
theme of a direct integration between signal-dependent mem-
brane trafficking events and transcription is a new and emerging
one. The only other example of a stimulus-induced nuclear
translocation of an endocytic protein is the EGF-dependent
translocation of APPL (adaptor protein containing PH domain,
PTB domain, and leucine zipper motif) to the nucleus, which
complexes with histone deacetylase multiprotein complex to
regulate chromatin structure and transcription (Miaczynska et
al., 2004). In contrast, HIP1 associates with a transcription fac-
tor, the AR, and perhaps other members of the nuclear hormone
receptor family to enhance their transcriptional activity.
The overexpression of HIP1 in prostate cancer, as an en-
docytic protein capable of translocating to the nucleus and co-
activating androgen-dependent transcription, is of potential
importance in the study of hormonal responses in prostate can-
cer. A major focus of the prostate cancer field thus far has been
on androgen hypersensitivity and kinase-dependent cross talk
between growth factor pathways and nuclear hormone recep-
tors rather than adaptor-based cross talk acting on both promot-
ers and membranes (Chen et al., 2004; Culig, 2004). Our work
now suggests that HIP1 may be capable of such integration
given the association with AREs and the coactivation of AR-
mediated transcription (Figs. 3 and 4).
 
HIP1 as a transcriptional regulator of 
the AR
 
It remains to be shown whether the association between HIP1
and the AR and between HIP1 and DNA is indirect or direct.
Immunoprecipitation has demonstrated an association between
the AR and the FxDxF/coiled coil domain of HIP1 (Fig. 2, A
and C). Mammalian two-hybrid assays suggest that the NH
 
2
 
-
terminal domain of the AR is a potential binding site for HIP1
(unpublished data). However, this region also binds other tran-
scriptional coregulators, which could act as a molecular bridge
to HIP1, and so more detailed mapping of the interaction site in
the AR is required (Metzler et al., 2001; Sampson et al., 2001;
Waelter et al., 2001).
The function of the I/LWEQ domain of HIP1 has previ-
ously proven difficult to confirm despite strong sequence homol-
ogy with well-characterized actin-binding proteins (Legendre-
Guillemin et al., 2002; Senetar et al., 2004). We have identified
an NLS within the COOH-terminal I/LWEQ domain, which
promotes the nuclear localization of GFP, and we believe that
this distinguishes HIP1 from its actin-binding homologues
(Figs. 6 A and 7). This motif may also explain a nuclear pool of
HIP1 of variable size observed in transfected and untransfected
COS7 cells by others (unpublished data). The NLS, although
not strong enough to localize GFP constitutively to the nucleus,
suggests that HIP1 may therefore have additional nuclear func-
tions and transcriptional effects that are independent of hor-
monal stimulation and AR expression.
HIP1 is believed to be recruited from the cytosol to mem-
branes through the binding of phosphoinositides by the ANTH
domain. We have demonstrated that the nuclear translocation
of HIP1 is an alternative dynamic event using cytosolic HIP1.
Ablating lipid binding and therefore membrane recruitment
with a double lysine mutation in the ANTH domain increases
the transcriptional coactivation of HIP1 (Figs. 6 and 8). The
Figure 8. Effects of lipid binding and NLS mutations on the coregulator
functions of HIP1. (A) COS7 cells were transiently transfected with
pcDNA3-HIP1, HIP1 K56E/K58E, or HIP1 R1005E constructs, pcDNA3-
AR and the pPSALuc reporter. Luciferase assays were performed after treat-
ment with 10 nM Mibolerone and 1  M Casodex. Data shown represent
the means of three independent experiments   SD. Lysates were blotted for
HIP1 and AR as well as actin as a loading control. (B) HIP1 R1005E was
transfected into LNCaP cells undergoing steroid depletion. Cells were
treated with 10 nM Mibolerone for 2 h, fixed, and stained for the AR (red)
and with a Myc antibody for HIP1 R1005E (green). Bar, 10  m. 
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NLS in HIP1 is also clearly equally important for the coactiva-
tor function of HIP1 because the R1005E mutation within this
motif converts HIP1 from a coactivator to a potent corepressor
(Fig. 8 A). Although this mutant can still bind to the AR (not
depicted), the steady-state distribution of AR in R1005E-trans-
fected cells is altered such that the AR appears largely cyto-
solic in certain cells (Fig. 8 B).
Other groups have in the past reported a requirement for
F-actin binding proteins in the nuclear translocation of the AR
although HIP1 itself has not been found so far to bind to F-actin
other than in vitro in biochemical experiments (Ozanne et al.,
2000; Schrantz et al., 2004; Senetar et al., 2004). Our findings
imply that the R1005E mutation exerts its influence on AR sig-
naling as a nuclear trafficking mutant by in part interfering with
nuclear entry after androgen treatment (Fig. 8 B and Fig. S2).
Previously, it has been reported that the AR shuttles in and
out of the nucleus several times after androgen treatment (Tyagi
et al., 2000). Given that the NLS in HIP1 is weak and that the
AR contains its own NLS motifs in the hinge domain, it is un-
likely that the R1005E HIP1 mutant could block the nuclear
translocation of the AR. The more plausible explanation must
therefore be that the association between HIP1 and the AR oc-
curs to some degree in the cytoplasm and affects the cycling and
turnover of the receptor. A role for HIP1 in regulating the degra-
dation or turnover of the AR is implied by the reduction in
steady-state AR levels induced by HIP1 siRNA and the in-
creased rate of AR degradation after the imposition of a cyclo-
heximide block (Fig. 5). A link between nuclear translocation of
the AR and its degradation was made when lysine mutations in
the NLS of AR were shown to delay nuclear entry of the protein
in response to ligand and inhibit proteasomal degradation
(Thomas et al., 2004). Degradation of native AR by a cytosolic
complex incorporating the E3 ubiquitin ligase, Hsc70 interact-
ing protein (CHIP), was recently reported (Thomas et al., 2004).
We therefore hypothesize that the R1005E mutant delays AR
nuclear translocation in response to ligand, thus making the re-
ceptor available to such a complex for degradation and so re-
pressing transcription. However, other factors that may contrib-
ute to the striking repressive effect of the R1005E mutant on
transcription by the AR include an alteration in the steady-state
nucleocytoplasmic distribution of the AR or disruption to the as-
sembly of an active AR transcription complex on promoters.
In conclusion, the field of endocytosis is now developed
enough for network theory to be applied to the large inventory
of adaptors and their protein–protein and protein–lipid interac-
tions (Praefcke et al., 2004). In contrast, mapping adaptor inter-
actions at a nuclear and promoter level, be it by ChIP-on-ChIP
or ChIP display, is only just beginning (Barski and Frenkel,
2004; Praefcke et al., 2004; Wang, 2005). HIP1 is an example
of an emerging subset of adaptor proteins capable of nuclear
translocation and associating with promoters and transcriptional
machinery. It and other adaptors have been linked with cancer
progression through correlative changes in expression and, in
leukemias, gene fusions. Although their mechanistic contribu-
tion to cancer progression remains to be elucidated, a role as
transcriptional regulators at promoters may prove as significant
as their involvement in membrane trafficking and endocytosis.
 
Materials and methods
 
Constructs and protein expression
 
Derivatives and mutants were subcloned into pGEX4T1 or 4T2, expressed
in 
 
E. coli
 
 BL21 cells, and affinity purified before use. HIP1 expression con-
structs were made with the pcDNA3.1 Myc-His6 expression vector as de-
scribed previously (Rao et al., 2002). GFP-tagged NLS constructs used
primers spanning aa 992–1009 ligated into the BamHI–NotI sites of the
NH
 
2
 
-terminal GFP-tagging vector pQN1-FC3 (Qbiogene), HIP1NLS
(GATCCGAATTGCAGGATCCAAGGAGCGTCAAAAACTGGGAGAGC-
TTCGGAAAAAGCACTACGAGGGC), and HIP1R-NLS (GATCCA-
CGGCTGAGGCTGAACGCATGCGGCTGGGGGAGTTGCGGAAGCA-
ACACTACGTGGGC). The K56E/K58E was made using sense and
antisense primers incorporating the appropriate single base changes
highlighted in bold: gtggctgta
 
g
 
aggaa
 
g
 
aacacgccagaacg and cgttctggcgt-
gtt
 
c
 
ttcct
 
c
 
tacagccac; and for the R1005E mutant using sense and antisense
primers: gggagagctt
 
ct
 
caaaaagcac and gtgcttttt
 
ga
 
gaagctctccc using two
cycling conditions for each construct. Cycling protocol 1: 13 cycles con-
sisting of 94
 
 
 
C for 40 s, 65
 
 
 
C for 30 s, and 70
 
 
 
C for 18 min and fol-
lowed by a final 67
 
 
 
C extension step lasting 18 min. Cycling protocol
2: 18 cycles consisting of 94
 
 
 
C for 40 s, 62
 
 
 
C for 30 s, and 67
 
 
 
C for 18
min and followed by a final 67
 
 
 
C extension step lasting 15 min. In both
cases the template DNA was digested using DpnI, with a 37
 
 
 
C incuba-
tion lasting 45 min and a subsequent denaturation step (65
 
 
 
C, 20 min)
before transformation into an XL-1 Blue strain of 
 
E. coli.
 
 An NH
 
2
 
-terminal
construct of HIP1 comprising aa 1–310 was PCR subcloned into the
EcoRI–NotI sites of pGEX4T2 using a sense (ggaattcatatggatcggatggc-
cagctccatgaag) and an antisense primer (ttttccttttgcggccgctaagggctgatat-
gttctgacagggctg).
The following expression vectors have previously been described:
pcDNA3-AR and TK-GAL4UASLuc, pPSALuc, pGAL4DBD-Er
 
 ,
pGAL4DBD-ER , MMTVLuc, pCMV- -gal, and pARE4-Luc (Brady et al.,
1999; Gaughan et al., 2001; Lu et al., 2001). pARE4-Luc consists of a
minimal promoter and was constructed by inserting four synthetic tandem
repeats of the ARE primers (5 -TGTACAGGATGTTCTGAATTCCATGTA-
CAGGATGTTCT-3  and 5 -AGAACATCCTGTACATGAATTCAAGAAC-
ATCCTGTACA-3 ) in front of an E1b minimal TATA box sequence, fol-
lowed by a firefly luciferase gene.
RNA interference
HIP1 knockdowns were performed using three siRNA constructs, which
were obtained as H1 cassettes (GenScript) and had the following sense
sequences: GAACCAAGAUGGAGUACCA (HIP1nts440-459); GCA-
CUACGAGCUUGCUGGU (HIP1nts3021-3039); GGACGAGGCUG-
GAGAAAGU (HIP1nts510-528). A scrambled siRNA was purchased from
QIAGEN and had the sequence UUCUCCGAACGUGUCACGUdTdT. In
brief, 250,000 LNCaP cells were plated onto a 24-well plate (Corning)
and left for 1 d to grow. On the day of transfection, 1  g of each oligo ei-
ther alone or in combination was transfected into individual wells at a ra-
tio of 1  g of oligo to 6  l of transfection reagent (RNAifect; QIAGEN)
according to the manufacturer’s guidelines.
Western blotting
Total cell extracts were prepared by lysing cells for 30 min on ice in lysis
buffer containing 50 mM Tris, pH 6.8, 150 mM NaCl, 50 mM sodium
glycerophosphate, 10 mM NaF, 1 mM sodium orthovanadate, complete
protease inhibitor (Roche), and 1% NP-40. The extracts were cleared by
centrifugation for 30 min at 17,000 g and then boiled in SDS sample
buffer for 10 min. Total cell lysate (20–30  g) was resolved by SDS-PAGE
(10% gel), transferred on to an Immobilon-P membrane (Millipore), and
the signal was visualized by ECL (GE Healthcare). Membranes were blot-
ted with antibodies against HIP1 (NOVUS Biologicals), AR (Santa Cruz
Biotechnology, Inc.), PSA (Santa Cruz Biotechnology, Inc.), lamin B (Santa
Cruz Biotechnology, Inc.), actin (Sigma-Aldrich), clathrin heavy chain
(Transduction Laboratories), GFP (CLONTECH Laboratories, Inc.), TGN46
(Serotec),  -adaptin (Sigma-Aldrich), Myc (Cell Signaling),  -tubulin, and
HIP1R (polyclonal: gift from T. Ross, University of Michigan Medical
School, Ann Arbor, MI).
Isolation of nuclear and cytosolic fractions from cell lines
Nuclei were isolated from LNCaP cells according to published protocols
(Schreiber et al., 1989). Confluent cells from 90-mm dishes were washed
twice in ice-cold TBS, and then gently scraped into 800  l of cold homog-
enization buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, and 0.5 mM PMSF) and allowed to swell on
ice for 15 min. Cells were lysed by addition of 50  l of a 10% solution ofHIP1 IS A NOVEL TRANSCRIPTIONAL COREGULATOR • MILLS ET AL. 199
NP-40 followed by 10-s vigorous vortexing. Nuclei were pelleted by cen-
trifugation at 14,000 rpm for 30 s. The cytoplasmic fraction was removed,
and nuclei were washed twice in homogenization buffer with NP-40 and
resuspended in 200  l of the same buffer. Nuclei were solubilized by soni-
cation, and protein concentrations of nuclear and cytoplasmic fractions
were determined using the BCA protein assay (Pierce Chemical Co.).
Equal amounts of protein from all fractions were boiled in 2  Laemmli
sample buffer, separated by SDS-PAGE, and transferred to nitrocellulose.
Membranes were blotted with antibodies to AR (Santa Cruz Biotechnol-
ogy, Inc.) and HIP1 (NOVUS Biologicals), as well as anti-lamin B (Santa
Cruz Biotechnology, Inc.) and clathrin heavy chain (Transduction Labora-
tories) that were used as nuclear and loading control probes. Primary an-
tibodies were followed up with appropriate HRP-conjugated secondary
antibodies (Dako). Immunoreactive bands were visualized with ECL using
SuperSignal substrate (Pierce Chemical Co.). Blots were scanned using a
densitometer (model FL-5000; Fuji) and band densities were quantitated
using ImageQuant software. Gel and blot images were prepared for the
illustrations with the use of Adobe Photoshop software.
CCV isolation
CCVs were isolated from LNCaP cells growing on six to eight 75-cm
2 tissue
culture flasks using an adaptation of an existing protocol (Hirst et al.,
2004). Protein levels were assayed, and equal protein loadings of the
fractions were blotted after SDS-PAGE.
Cell culture and microscopy
COS7 and LNCaP lines were grown in DME and RPMI-1640 media,
respectively, supplemented with 10% FBS or charcoal-stripped FBS
(Hyclone). Cells were grown in steroid-depleted media for 48 h pretrans-
fection and were then transfected with Fugene according to the manufac-
turer’s protocol. Cells were fixed with 3% PFA, followed by permeabiliza-
tion with 0.1% saponin. Primary antibodies are listed in the Western
blotting section; secondary antibodies were purchased from Molecular
Probes. Images were acquired on a confocal microscope (model LSM510
META; Carl Zeiss MicroImaging, Inc.) equipped with the appropriate fil-
ters and laser lines. Images were rendered in image browser software
(Carl Zeiss MicroImaging, Inc.) before processing for publication using
Adobe Photoshop.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from growing LNCaP cells using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. Real-time PCRs
were performed using a SYBR Green PCR Master Mix (Applied Biosys-
tems) in an ABI PRISM 7900HT Sequence Detection System (Applied Bio-
systems) according to the manufacturer’s instructions. Cycling conditions
were 50 C for 2 min, 95 C for 10 min, 40 cycles of 95 C for 15 s, and
60 C for 1 min. The following primer pairs were used to profile the AR
(CTCACCAAGCTCCTGGACTC and CAGGCAGAAGACATCTGAAAG),
PSA (GCAGCATTGAACCAGAGGAG and AGAACTGGGGAGGCT-
TGAGT), HIP1 (CAACCCTGGCGAACAGTTCTA and TCCAAATGAC-
CGAAGCTCG), HIP1R (CACGCAGCAGGAATTTTACGC and CCTCAT-
ACTTGCCCGTGTGAA), and  -actin (CACAGCTGAGAGGGAAATC and
TCAGCAATGCCTGGGTAC).
Luciferase reporter assays
GAL4-based reporter assay. For transcriptional assays, HIP1 and its trun-
cated versions were cloned into the PM2 vector fused to the GAL4 DNA-
binding domain (aa positions 1–147). COS-7 cells grown in 6-well dishes
were transiently transfected in triplicate with 0.3  g of the GAL4-TK-
luciferase reporter and with 1.2  g of the different GAL4 fusion constructs
using lipofectamine (Invitrogen). Cells were lysed after 48 h and analyzed
by immunoblotting with anti-GAL4 antibodies (Santa Cruz Biotechnology,
Inc.) to verify the levels of expression of the various GAL4 fusion proteins.
Transactivation assays were performed only on sets of transfectants that
showed comparable levels of expression of the various proteins. Luciferase
activity was measured on identical amounts of total cellular lysates from the
various transfectants using a commercial kit (Promega).
Androgen reporter assay. Cells were seeded into 24-well plates
and grown in the presence of charcoal-stripped medium for at least 24 h
before transfection with a PSA luciferase reporter construct (pPSALuc) and
a  -Gal reporter. Reporter assays were undertaken as described previ-
ously (Gaughan et al., 2002). All experiments shown are the average of
at least three independent experiments performed in triplicate   SD.
Liposome sedimentation assay. Sedimentation assays were per-
formed according to an established protocol (Peter et al., 2004). Recombi-
nant protein was expressed and purified from BL21 DE3 cells. Liposomes
consisting either of 40% phosphatidylcholine, 40% phosphatidylethanol-
amine,10% cholesterol, and 10% phoshatidylinositol (Avanti Polar Lipids,
Inc.) or of Folch fraction1/total bovine brain lipids (Folch fraction 1;
Sigma-Aldrich B1502) were resuspended at 1 mg/ml in 20 mM Hepes,
pH 7.4, 150 mM NaCl, and 1 mM DTT and sized by extrusion. Superna-
tants and pellets were resuspended in an equal volume of sample buffer
and subjected to SDS-PAGE and visualized by Coomassie stain.
ChIP. ChIP assays were performed as described previously (Gau-
ghan et al., 2002). For immunoprecipitation, 2  g of polyclonal AR
and 2  g monoclonal HIP1 antibodies were used as indicated. ReChIP
analysis was performed as described previously (Reid et al., 2003). In
brief, AR and HIP1 antibodies were added to chromatin extracts for 5 h
followed by the addition of 60  l of salmon sperm/protein A–Agarose
(Upstate Biotechnology) to recover immunocomplexes. AR- and HIP1-con-
taining complexes were eluted by 1-h incubation in reChIP buffer (0.5 mM
DTT, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris, pH
8.1) and subsequently reimmunoprecipitated by the addition of 2  g of
antibodies for AR, HIP1, or anti-VP16 for control, to an equal volume of
eluted material. Recovery and preparation of DNA was performed as de-
scribed previously (Gaughan et al., 2002). Semi-quantitative PCR was
performed with 10  l of DNA, BioTaq DNA polymerase, and  -[
32P]dATP,
using the following primers: ARE IF, TCTGCCTTTGTCCCCTAGAT, and
ARE IR, AACCTTCATTCCCCAGGACT, to amplify 235 bp of the proximal
PSA promoter, encompassing the ARE I (Fig. 4 A); ARE IIIF, CCTCCCAG-
GTTCAAGTGATT, and ARE IIIR, GCCTGTAATCCCAGCACTTT, to am-
plify the distal ARE III; ARE XF, CTGTGCTTGGAGTTTACCTGA, and ARE
XR, GCAGAGGTTGCAGTGAGCC, to amplify a non-ARE–containing por-
tion of the PSA promoter. PCR products were resolved, dried, and then ex-
posed to X-ray film for 2–12 h. ChIP data are representative of triplicate
experiments performed using similar passage number LNCaP cells.
Online supplemental material
Fig. S1 shows coactivation of estrogen and glucocorticoid receptors by
HIP1. HIP1 was cotransfected into COS7 cells with the estrogen or gluco-
corticoid receptors along with appropriate luciferase reporter constructs.
Lysates were assayed for luciferase activity. Experiments were performed
in triplicate and SDs are shown. Fig. S2 shows the effect of the HIP1
R1005E mutant on the nucleocytoplasmic distribution of the AR. LNCaP
cells were transfected with Myc-tagged wtHIP1 or HIP1 R1005E and frac-
tionated after androgen treatment. Nuclear and cytosolic fractions were
resolved by SDS-PAGE and blotted for the AR and Myc illustrated with rep-
resentative blots (Fig. S2 A). Fractions were also blotted for lamin B and
clathrin as nuclear and cytosolic control proteins (Fig. S2 C). The degree
of translocation of the AR and HIP1 was quantitated by densitometric anal-
ysis of the blots (Fig. S2 B). Experiments were performed five times and
SDs are shown. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200503106/DC1.
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